Novartis, Boehringer DTC platforms slash prices for Cosentyx, Spiriva Respimat

29th September 2025 Uncategorised 0

In laying out their respective plans Monday to launch new direct-to-patient platforms paring down the prices of popular medicines in the U.S., Novartis and Boehringer Ingelheim are falling in line with demands from President Donald Trump and joining the likes of AstraZeneca and Bristol Myers Squibb.

More: Novartis, Boehringer DTC platforms slash prices for Cosentyx, Spiriva Respimat
Source: fierce